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Abstract 
In 1990 the role of basement membranes in human disease was established by the 
identification of COL4A5 mutations in Alport’s syndrome. Since then the number of 
diseases caused by mutations in basement membrane components has steadily increased as 
has our understanding of the roles of basement membranes in organ development and 
function. However, many questions remain as to the molecular and cellular consequences 
of these mutations and how they lead to the observed disease phenotypes. Despite this, 
exciting progress has recently been made with potential treatment options for some of these 
so far incurable diseases. 
 
Introduction 
Basement membranes (BM) are specialised extracellular matrices that provide tissue 
structure and influence cell behaviour. They are present throughout the body and form 
compartments within tissues by separating endothelial and epithelial cells from underlying 
mesenchyme. In general BMs are composed of collagens, perlecan, nidogens and laminins, 
but individual BMs differ in their composition leading to an abundance of different 
interacting partners and added complexity. Consequently BMs are crucial to life and 
mutations in their components lead to a wide variety of clinical phenotypes affecting 
different organs. In this review we will cover after a short overview of the main BM 
components, the current knowledge of diseases caused by abnormalities of these molecules 
in the eye, kidney, vasculature, skin and neuro-muscular junction.  
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Laminins 
Laminin is besides collagen type IV the most abundant basement membrane component 
and is present in all BMs. A laminin network links the BM to the cell surface through 
interactions with cell surface receptors, which enables it to influence cell signalling and 
behaviour besides providing a structural role. Laminins are heterotrimeric glycoproteins 
consisting of an α, β and γ chain, and 5 α, 3 β and 3 γ chains are encoded by the genes 
LAMA1-5, LAMB1-3 and LAMC1-3 (Durbeej 2009). The chains can assemble into at least 
15 laminin proteins (Miner 2008) which are named in the new nomenclature according to 
their composition such that LM-111 consists of the α 1, β 1 and γ 1 chains (Aumailley et al. 
2005). As some chains are components of multiple laminins, e.g. laminin α5 chain is a 
component of LM-511, LM-521 and LM-523, characterising the role of individual laminins 
is difficult as mutations may affect multiple laminins.  
Generally, laminins are cruciform shaped proteins (Fig. 1), although rod- or Y-shaped 
laminin molecules occur (Durbeej 2009).The N-terminal end of the chains contains 
globular domains separated by laminin epidermal growth factor-like repeats (LEa, LEb, 
LEc). All chains contain laminin N-terminal (LN) domains which are important for laminin 
network formation. The α chain also contain the L4a and L4b globular domains whilst β 
and γ chains contain the LF and L4 domains respectively. The central coiled coil region is 
flanked by the C-terminal end of the α chain which forms the globular LG domain, 
consisting of five LG domains which mediate cell adhesion through binding receptors 
including integrins, dystroglycan, syndecan and heparin (Miner 2008). These interactions 
can be modulated by the proteolytical cleavage of LG domains 3-5.  
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Because laminin, collagen type IV, nidogen and perlecan are key BM components, one can 
imagine that aberrations in any of these components would prohibit BM formation. The 
absence of BM formation in mice deficient for laminin γ1 or β1 (Miner et al. 2004; Smyth 
et al. 1999) shows indeed that laminin is required for initial BM formation and early 
development. In contrast, collagen type IV (Poschl et al. 2004), nidogen (Bader et al. 2005) 
and perlecan (Arikawa-Hirasawa et al. 1999) are required for BM maintenance rather than 
initial formation. Laminin’s role in development is not limited to early development as both 
the interaction between nidogen and laminin γ1 and laminin α5 are required for kidney 
formation (Miner and Li 2000; Willem et al. 2002). In addition, laminin α5 plays a role in 
the development of placenta, brain, limb and lung (Miner 2008), and elegant rescue 
experiments have begun to address how laminin α5 functions. These data showed that 
during development its role is mediated through the LG1-2 domains whilst the LG3-5 
domains functions in the glomerular filtration barrier (Kikkawa and Miner 2006). 
One of the central concepts observed following laminin deficiency is the induced 
expression of other laminins. The effectiveness of this for organ function depends on the 
redundancy of the different laminin molecules as illustrated by the successful compensatory 
expression in notochord development of laminin α4 following laminin α1 deficiency in 
zebrafish (Pollard et al. 2006). However this compensation may not always restore organ 
function as laminin β1 expression in the glomerular basement membrane (GBM) of Lamb2-
/- mice does not rescue filtration barrier function despite producing a structurally intact BM 
(Noakes et al. 1995b).  
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BMs underlying stratified epithelia, such as skin, contain laminins with α3 and α5 chains 
(Aumailley et al. 2006) which form LM-332 (previously known as laminin 5) and LM-311 
(laminin 6) which together with the ectodomain of collagen XVII constitutes the anchoring 
filaments (Nonaka et al. 2000; Rousselle et al. 1991). LM- 511 (laminin 10), more 
ubiquitous than the preceding laminins, is also present at the dermal-epidermal junction. 
The N-termini of LM-332 binds to collagen VII, a major component of the anchoring fibrils 
thereby connecting anchoring filaments with fibrils. In contrast to other laminin molecules, 
LM-332 may rely on the association with LM-331 to form oligomers as it can not self-
polymerize (Aumailley et al. 2006). In addition nidogen 1, fibulin-1 and -2 can bind the 
recombinant N-terminal region of the γ2 chain of laminin 332 (Sasaki et al. 2001). These 
interactions may be important for integration of LM-332 into the extracellular matrix before 
maturation of the γ2 chain (Gagnoux-Palacios et al. 2001), as a substantial portion of the N-
terminus of the γ2 chain is cleaved in human adult skin (Tunggal et al. 2002). 
 
Collagens  
Collagens are the major structural component of the extracellular matrix but are also 
important for tissue architecture organisation and cellular processes such as adhesion and 
migration. The interactions of collagens with extracellular matrix proteins and cell surface 
receptors are important during processes such as development, growth, tissue remodelling 
and disease pathologies. Currently 28 different types of collagen are known, which can be 
grouped in subfamilies such as fibrillar collagens, FACITs (fibril-associated collagens with 
interrupted triple helices), transmembrane collagens and network forming collagens 
(Myllyharju and Kivirikko 2004) (see also (Gordon and Hahn 2009) in this issue). All 
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collagen proteins contain one or more collagenous domains consisting of GLY-X-Y amino 
acid repeats and many human mutations affect this glycine residue, which is crucial for 
formation of the triple helical structure of collagen (Myllyharju and Kivirikko 2004).  
 
Collagen type IV 
Collagen type IV is the most abundant structural BM component and vertebrates express 
six α(IV) chains, encoded by the genes COL4A1-COL4A6, which are genomically 
organised in pairs in a head to head fashion (COL4A1 with COL4A2, COL4A3 with 
COL4A4 and COl4A5 with COL4A6). In each alpha chain the central collagen domain is 
flanked by an N-terminal 7S domain and a C-terminal non-collageneous domain (NC1) 
(Fig 2A) (Khoshnoodi et al. 2008).  
In the endoplasmic reticulum (ER) three alpha chains fold to form a heterotrimeric 
molecule, called protomer, and despite the 56 possible combinations, only three different 
protomers, α1.α1.α2(IV), α3.α4.α5(IV) and α5.α5.α6(IV), have been described. Protomer 
formation occurs through the interaction of three NC1 domains and protomer composition 
is determined by the relative affinity of NC1 domains for different alpha chains and the 
presence of recognition sites on NC1 domains (Khoshnoodi et al. 2006). Following 
establishment of the NC1 trimer, triple helix formation occurs in a zipper like fashion and 
protomer secretion occurs. Once secreted, a complex set of interactions occurs between 
protomers forming a collagen type IV network in the shape of a lattice. Two protomers 
interact to form a dimer with a NC1 hexamer and four protomers interact through 
interactions between residues of the 7S domains. Finally, triple helical domains can also 
interact with each other (Khoshnoodi et al. 2008). 
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The collagen type IV networks are differentially expressed with α1.α1.α2(IV) being the 
most widely expressed throughout embryonic development. The onset of α3.α4.α5(IV) and 
α5.α5.α6(IV) expression is later in development and in some renal and testicular basement 
membranes α3.α4.α5(IV) replaces α1.α1.α2(IV) (Harvey et al. 2006; Kalluri et al. 1997).  
Despite being a predominant component of all BMs, collagen type IV is not required for 
BM formation but is necessary for BM maintenance (Poschl et al. 2004). The important 
structural role of collagen type IV is illustrated by the clinical consequences of collagen IV 
mutations (see below), and the defective placental structure and haemorrhaging, due to BM 
defects, in α1.α1.α2(IV) deficient mice (Poschl et al. 2004).  
In addition, collagen type IV mediates cell adhesion to the BM through binding to integrin 
and non-integrin receptors. Collagen type IV interacts mainly with β1 integrin receptors 
(Leitinger and Hohenester 2007), in particular α2β1 and α1β1 integrin, through sequences in 
the collagen and NC1 domains (Khoshnoodi et al. 2008) (Fig. 2A). Integrin binding is 
important during angiogenesis as the NC1 derived fragments of α1(IV) (arresten), and α3 
(IV) (tumstatin) rely on α1β1 and αvβ3 integrin interactions respectively for their 
antiangiogenic capabilities (Mundel and Kalluri 2007). Finally during angiogenesis, 
exposure of cryptic integrin binding sites may occur due to the proteolytic degradation or 
denaturation of collagen type IV, and antibodies against these sites may inhibit 
angiogenesis (Xu et al. 2001). 
Besides integrin receptors, collagen type IV also binds DDR1 (Discoidin Domain Receptor 
I), a tyrosine kinase receptor that becomes phosphorylated following collagen binding 
(Leitinger and Hohenester 2007). The physiological importance of the interaction is 
underlined by the different renal phenotypes including proteinuria and GBM thickening of 
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DDR1-deficient animals, (Gross et al. 2004), similar to phenotypes relevant to collagen 
type IV pathology (see below).  
 
Collagen type XVIII, XV and endostatin 
Collagen type XVIII belongs to the multiplexin (multiple triple-helix domains with 
interruptions) subfamily of collagen proteins and is a heparin sulphate proteoglycan, 
consisting of a protein core with negatively charged heparan sulphate side chains. Besides 
perlecan and agrin, it is the third main heparan sulphate proteoglycan of the BM and is 
structurally similar to the chondroitin sulphate proteoglycan collagen type XV (Iozzo 
2005).  
Collagen type XVIII is expressed in BMs underlying epithelial and endothelial cells and 
has three isoforms, with different N-terminal fragments, that exhibit specific expression 
patterns (Marneros and Olsen 2005). Collagen type XVIII displays a polarised position in 
BMs as its C-terminal domain is embedded in the lamina densa, where it interacts with 
perlecan and laminins, whilst in most BMs, the N-terminal domain extends into the matrix 
below the lamina densa of the BM (Elamaa et al. 2005).  
The central domain of collagen type XVIII consists of collagenous repeats separated by 
non-collagenous regions. This central domain is flanked by an N-terminal domain with 
thrombospondin-1-like and frizzled motifs which can inhibit Wnt signalling (Quelard et al. 
2008), and a C-terminal trimerisation domain which harbours the fragment endostatin, also 
present in collagen type XV (Sasaki et al. 2000). The release of endostatin, through 
cleavage of the hinge that separates the C-terminal domain from the triple helical domain 
occurs in vivo as endostatin can be detected in plasma and tissue extracts (Iozzo 2005). 
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Endostatin has been heavily investigated due to its anti angiogenic activity (Iozzo 2005), 
although the absence of a difference in tumour growth in endostatin deficient mice 
challenged with fibrosarcoma and melanoma (Fukai et al. 2002) questioned the anti-
angiogenic role of endogenous endostatin. However evidence showing increased vascular 
outgrowth in aortic explant cultures (Li and Olsen 2004) and increased levels of corneal 
neovascularisation (Marneros et al. 2007) in Col18a1–/– mice, do support an antiangiogenic 
role for endogenous endostatin which relies at least in part on binding heparan sulphate 
proteoglycans such as perlecan and αvβ5-integrin (Iozzo 2005).  
In contrast to the C-terminal end, the function of the N-terminal domain is much less 
characterised but analysis of the inner limiting membrane (ILM) in eyes suggests it may 
function in anchoring the BM to underlying structures (Fukai et al. 2002).  
Despite their structural similarity collagen type XVIII and XV, have separate biological 
roles as Col15a1-/- animals display muscle defects (Eklund et al. 2001) compared to the eye 
phenotype of Col18-/- mice (see below). 
 
Epithelial specific collagens, types VII and XVII 
Collagen type VII and XVII, and their ligand LM-332, occur mainly in BMs below 
stratified squamous epithelia in skin and mucous membranes of the orifices, where they 
function as components of the hemidesmosome-anchoring filament–anchoring fibril 
adhesion complex, which attaches the epithelium to the underlying dermal mesenchyme.   
Collagen type XVII belongs to the family of transmembrane collagens and is a homotrimer 
of α1(XVII) chains (Fig 2C) (Franzke et al. 2005). The intracellular domain of collagen 
type XVII co-localises and interacts with the intracellular tail of integrin β4, BP230 and 
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plectin (Hopkinson and Jones 2000; Koster et al. 2003) in the cytoplasmic plaque of 
hemidesmosomes. The ectodomain of human collagen type XVII, contains collagenous 
domains (Col1-15), interspaced by non-collagenous (NC1 to NC16) segments and its 
tertiary structure is longitudinal with a C-terminal flexible tail (Franzke et al. 2005) (Fig. 
2C). Sheddases of the ADAMS (a disintegrin and metalloproteinase) family release the 
ectodomain from the cell surface by cleavage within the NC16 domain (Franzke et al. 
2005) which can also interact with the extracellular stalk of integrin α6 (Hopkinson and 
Jones 2000), at least in vitro. The ectodomain of collagen type XVII co-localizes with LM-
332 in the anchoring filaments, and its C-terminus reaches the lamina densa (Nonaka et al. 
2000) and binds to laminin 332 (Tasanen et al. 2004), suggesting that the C-terminal end of 
collagen type XVII is important for the spatial orientation of laminin 332 and its 
localization in the collagen type IV-containing lamina densa.  
 
Collagen type VII is the largest collagen and the main structural component of the 
anchoring fibrils, which attach the BM with the papillary dermis in the skin (Aumailley et 
al. 2006). It is synthesized as a proα1(VII) polypeptide chain that contains an amino-
terminal globular domain named NC-1, a central triple-helical domain and a small c-
terminal globular domain termed NC-2 (Fig. 2D). The pro-collagen type VII molecule is a 
homotrimer of proα1(VII)-chains and each pro-collagen molecule forms an anti-parallel 
dimer, with a short C-terminal overlap and disulfide-bonding (Chen et al. 2001). Finally, 
dimers aggregate laterally to form the anchoring fibrils. During the biosynthesis and the 
supra-molecular aggregation of the fibrils, pro-collagen type VII is processed to mature 
collagen via proteolytic processing of the NC-2 domain by BMP-1 (bone morphogenic 
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protein-1) (Rattenholl et al. 2002). Both keratinocytes and fibroblasts can synthesize 
collagen type VII and interactions between collagen VII and laminin 332 (Chen et al. 1997; 
Rousselle et al. 1997; Tasanen et al. 2004) or banded collagen fibrils (Villone et al. 2008) 
in the skin stabilize the DEJ (dermo epidermal junction). 
 
Perlecan  
Perlecan (HSPG2) is a large heparan sulphate proteoglycan (see also (Schäfer and Schäfer 
2009) in this issue) that is present in BMs. It can also be found at the cell surface and in 
tissues such as cartilage and connective tissue stroma (Iozzo 2005; Schäfer and Schäfer 
2009). Numerous binding partners have been identified including other BM components 
(nidogen and collagen type IV), integrins and growth factors (Fig. 3) which may underlie 
some of the functions of perlecan such as cell and growth factor signalling, direction of 
neurite outgrowth, ligand internalisation signal and BM maintenance (Schäfer and Schäfer 
2009).  
Perlecan consists of 5 domains (Fig. 4). Domain I is the attachment site for the heparan 
sulphate chains whilst domain II is homologous to the low density lipid receptor ligand 
binding domain. Domain III has laminin-like domain modules and epidermal growth factor 
(EGF)-like repeats whilst domain IV is important for BM integration by binding other BM 
components (Hopf et al. 1999). The C-terminal domain V contains the fragment 
endorepellin (Iozzo 2005).  
Analysis of perlecan functions has been greatly aided by the generation of the perlecan 
knock-out mouse model, which develops a lethal multi organ phenotype affecting heart, 
brain and cartilage development (Costell et al. 1999) underscoring the importance of 
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perlecan for development. A viable mouse model (Hspg2Δ3/Δ3) harbouring a deletion of 
exon 3, which greatly reduces the amount of heparan sulphate side chains (Tran et al. 
2004), has enabled the elucidation of the relative contributions of the core protein versus 
the side chains to perlecan function. 
Similarly to the C-terminal fragments of collagens type IV (tumstatin, arresten), XV and 
XVIII (endostatin), endorepellin possesses anti- angiogenic activity (see also (Pihlajaniemi 
and Soininen 2009) in this issue), both in vitro and in vivo which is mediated through the 
interaction with α2β1 integrin (Iozzo 2005; Woodall et al. 2008). In contrast to 
endorepellin, perlecan itself seems to support tumour and developmental angiogenesis as it 
promotes tumour growth (Iozzo 2005) and perlecan knockdown in zebrafish affects the 
sprouting of intersegmental vessels (Zoeller et al. 2008). This activity seems to be mediated 
through binding of fibroblast growth factors by its heparan sulphate side chains (Mongiat et 
al. 2000; Zhou et al. 2004), FGF2 and bFGF (Aviezer et al. 1994; Sharma et al. 1998).  
 
Nidogen 
All basement membranes contain nidogen and vertebrates express two nidogens, nidogen 1 
and nidogen 2, which are sulphated glycoproteins. Although in some BMs, e.g. kidney and 
blood vessels, both proteins co-localise in general the expression of nidogen 2 is more 
restricted than that of nidogen 1 (Ho et al. 2008).  
Nidogens consist of 3 globular domains (G1-3) connected by rod-like or thin segment 
domains (Ho et al. 2008), which can interact with BM components and integrin receptors 
(Fig. 4). The ability to bind perlecan, laminin and collagen type IV (Gerl et al. 1991; Mayer 
et al. 1993), led to the hypothesis that nidogen acts as an essential bridge between BM 
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components (Ho et al. 2008). However, this was challenged by the results that a loss of 
function mutation of nidogen in C. elegans does not affect BM assembly (Kang and 
Kramer 2000; Kim and Wadsworth 2000) and that Nid1-/- mice have a normal BM structure 
and no pathological features (Murshed et al. 2000). The presence of cardiac, kidney, lung, 
and limb defects in perinatal lethal Nid1-/-Nid2-/- mice associated with BM defects (Bader et 
al. 2005; Bose et al. 2006) showed that nidogen 2 compensates for the absence of nidogen 1 
(Bader et al. 2005).  
At least some of the functions of nidogen are mediated through its interacting partners. 
Deletion of the nidogen binding site in laminin γ1 (formerly known as γ1III4 but in new 
nomenclature γ1LEb3) demonstrated that nidogen functions mediated through laminin are 
important for lung and kidney development, as both γ1LEb3 and Nid1-/- Nid2-/- mice 
exhibited delayed lung development (Bader et al. 2005; Willem et al. 2002) and renal 
agenesis was observed in γ1LEb3 mice (Willem et al. 2002). In limb development, nidogen 
may function through perlecan as limb defects in Nid1-/-Nid2-/- mice are associated with 
aberrant FGF8 signalling (Bose et al. 2006) and perlecan plays a role in growth factor 
signalling. The observation of defective BMs in these models show that nidogen 1 and the 
laminin nidogen interaction are not required for BM formation but are necessary for the 
maintenance of particular BMs but not for other BMs (Kang and Kramer 2000; Kim and 
Wadsworth 2000; Mokkapati et al. 2008). The necessity of nidogen for BM function may 
depend on the composition of individual BMs and/or compensation by other BM proteins. 
Detailed investigation of animal models should enable the elucidation of this important 
question and may identify putative disease processes caused by nidogen abnormalities as 
thus far no nidogen mutations have been described in human disease.  
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 Human diseases caused by mutations in basement membrane components 
Mutations in BM proteins result in phenotypes in a few organs, and the molecular disease 
mechanisms are still not fully understood. The restricted number of affected tissues is 
perhaps surprising considering the wide expression patterns of BM proteins. Future 
research will likely disclose phenotypic, functional variations that depend on the exact 
location of the mutation within the BM molecule, e.g. at ligand binding sites, and the role 
of genetic modifiers in different organs and diseases. Below, the current knowledge of BM 
diseases is summarized. 
 
Kidney 
The kidney contains three BMs; a tubular BM, the glomerular BM (GBM) and the BM of 
Bowman’s capsule, in addition to the vascular BMs. The GBM is an integral part of the 
filtration apparatus, as it separates the glomerular endothelial cells from the podocytes 
(specialised epithelial cells) and their foot processes. In addition to structural support, the 
GBM plays an important functional role in the filtration process by forming an albumin 
barrier (Jarad et al. 2006).  
 
Alport’s syndrome, thin basement nephropathy and diffuse leiomyomatosis 
Alport’s syndrome affects mainly the kidney, with hematuria, interstitial nephritis and 
progressive renal failure as major symptoms, but patients can also develop sensorineural 
deafness, lenticonus of the anterior capsule (a protrusion of the lens) and dot fleck 
reflection (retinopathy) (Gubler 2008; Hudson et al. 2003). Kidneys display progressive 
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thickening of the GBM resulting in splitting and multilamellations, and areas of BM 
thinning leading to a basket weave appearance.  
Alport’s syndrome is caused by COL4A5, COL4A3 or COL4A4 mutations. COL4A3 or 
COL4A4 mutations only impact on the α3.α4.α5(IV) network, but COL4A5 mutations 
affect both the α3.α4.α5(IV) and α5.α5.α6(IV) networks (Gubler 2008). The inheritance 
can be X-linked (COL4A5 mutations, 85% of all cases), autosomal recessive (COL4A3 or 
COL4A4 mutations, 10-15%) or autosomal dominant (COL4A3 or COL4A4 mutations, 0-5 
%) (Hudson et al. 2003). Deletion, insertion, splice site and missense mutations have been 
described and the majority of missense mutations affect the glycine residues of the Gly-X-
Y repeat. Patients with autosomal recessive disease carry compound heterozygous or 
homozygous COL4A3 or COL4A4 mutations (Gubler 2008; Hudson et al. 2003).  
The age of onset and phenotypic severity of Alport’s syndrome is variable and depends on 
inheritance pattern and type and location of the mutation. In general, early onset end stage 
renal disease is observed in autosomal recessive Alport’s syndrome, whereas the autosomal 
dominant form may not progress to end stage renal disease (Hudson et al. 2003). In 
addition insertion and deletion COL4A5 mutations result in a juvenile age of onset whilst 
the position of missense mutation affects the age of onset and disease severity (Gubler 
2008). Finally, X chromosome inactivation greatly influences severity in female carriers of 
X-linked Alport’s syndrome and lends the disease a wide range of phenotypes (Gubler 
2008). It has been widely regarded that the main causative mechanism in Alport’s 
syndrome is the absence of the α3.α4.α5(IV) network in the adult mature GBM as 
observed by a lack of immunostaining (Gubler 2008). This can also be observed in female 
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carriers of COL4A5 mutations and female Col4a5-/- mice which have a characteristic 
mosaic expression pattern due to X chromosome inactivation. 
In contrast to the α1.α1.α2(IV) network in the foetal GBM, the α3.α4.α5(IV) network of 
the mature GBM has a higher degree of crosslinking and resistance to proteolysis (Kalluri 
et al. 1997) which may be required to cope with the increased stress of the adult kidney. 
This hypothesis is supported by the presence of structural abnormalities in mature GBM in 
X-linked Alport’s syndrome that contain α1.α1.α2(IV), and filtration defects in Col4a3-/- 
mice in areas of the GBM that are structurally normal (Abrahamson et al. 2007).  
Analysis of Col4a3-/- mice revealed that genetic modifiers can influence phenotype severity 
by inducing the expression of α5.α5.α6(IV) in the GBM, thereby resulting in a delayed age 
of onset of renal failure (Kang et al. 2006). Moreover, although the actual contribution to 
the phenotype of altered laminin α5 and α1 expression in the GBM of Col4a3-/- mice 
(Abrahamson et al. 2007) remains to be determined, the above data do suggest that clinical 
severity and disease progression in Alport's syndrome is subject to multiple modifiers. This 
knowledge may shed light on potential treatment options. 
 
Carriers in families with autosomal Alport’s syndrome may present with hematuria and 
basement membrane thinning (Hudson et al. 2003). These symptoms also occur in 
individuals diagnosed with “thin basement membrane nephropathy (TBMN)” (also known 
as benign familial hematuria). The clinical similarity may not be surprising as 40% of 
TBMN cases are due to COL4A3 or COL4A4 mutations (Gubler 2008). Traditionally 
TBMN has been considered a benign disorder as it often does not progress to renal failure. 
However, longitudinal analysis of patients challenged this assumption, since 30% develop 
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chronic renal failure and 20% end stage renal disease (Voskarides et al. 2007), compared to 
24% of autosomal dominant Alport’s syndrome patients that develop end stage renal 
disease (Marcocci et al. 2009). In addition, heterozygous Col4a3+/- mice, which exhibit 
TBMN, develop chronic renal failure and have a reduced life expectancy (Beirowski et al. 
2006). Consequently, these data question the separate entity of TBMN and suggest it could 
be considered a mild form of Alport´s syndrome (Hudson et al. 2003).  
 
X-linked Alport’s syndrome may occur combined with diffuse leiomyomatosis, a disorder 
characterized by benign smooth muscle tumours leading to oesophageal dysfunction and 
genital leiomyomas (Hudson et al. 2003). Diffuse leiomyomatosis is caused by deletions 
affecting both COL4A5 and the first two exons of COL4A6 due to deletion breakpoints in 
intron 2 of COL4A6. Although the deletions abrogate both α3.α4.α5(IV) and 
α5.α5.α6(IV), dominant negative effect are also possible as deletions extending beyond 
exon 3 of COL4A6 do not cause diffuse leiomyomatosis (Heidet et al. 1995), indicating that 
COL4A6 deficiency is not responsible for tumour formation. A further possibility is that 
the deletions may alter expression of other genes through removal of regulatory elements 
such as silencers/enhancers or non coding RNAs which may increase cell proliferation 
(Hammond 2006).  
 
COL4A1 mutations, HANAC syndrome and polycystic kidney disease 
The role of α1.α1.α2(IV) in human disease was unknown until the recent analysis of ENU 
(N-ethyl-N-nitrosourea, a powerful mutagen that results in single base pair mutations) 
mouse models with Col4a1 mutations which led to the identification of patients with 
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COL4A1 mutations. In mice, Col4a1 missense mutations caused a mild glomerulopathy 
with extensive BM defects in Bowman’s capsule (Fig. 5) (Van Agtmael et al. 2005), mild 
BM abnormalities in the GBM, and proteinuria (Favor et al. 2007; Gould et al. 2006). Some 
of these phenotypes were also observed in HANAC syndrome (hereditary angiopathy with 
nephropathy, aneurysm and cramps) caused by COL4A1 missense mutations. The patients 
exhibit a normal GBM but display defects in the BM of Bowman’s capsule, tubules and 
arterioles (Plaisier et al. 2007). Clinically, HANAC patients develop kidney phenotypes, 
including hematuria, reduced glomerular filtration rate (although no kidney failure is 
observed) and cystic kidney disease, in addition to eye and vascular pathology (see below). 
Some phenotypes may develop with age, as the cystic kidney disease was observed only in 
older patients (Plaisier et al. 2007).  
Currently all mutations identified in HANAC syndrome are located in COL4A1 exons 24 or 
25 (Plaisier et al. 2007). Other COL4A1 mutations have been described in families with 
vascular and eye disease (Breedveld et al. 2006; de Vries et al. 2009; Gould et al. 2005; 
Gould et al. 2006; Shah et al. 2009; Vahedi et al. 2007b; van der Knaap et al. 2006) (see 
below), but it is not known whether these patients have renal phenotypes. Analysis of 
patients and ENU mouse models with COL4A1 mutations has revealed that the mutations 
result in a spectrum of phenotypes determined by the individual mutation (Van Agtmael et 
al. 2005), its location within the gene and genetic and environmental modifiers(Gould et al. 
2007; Gould et al. 2006). Mutations affecting the Y residue of the G-X-Y repeat or residues 
in the NC1 domain result in milder phenotypes than mutations affecting glycine residues 
(Favor et al. 2007; Van Agtmael et al. 2005). This difference was also observed at the BM 
level suggesting BM defects underlie the phenotypes (Van Agtmael et al. 2005). In this 
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case the mutation may result in focal absence of α1.α1.α2(IV) and/or affect interactions 
with collagen type IV receptors such as integrins and DDR1, or other BM components. 
However, the presence of swollen ER vesicles (Gould et al. 2005; Van Agtmael et al. 2005) 
and increased expression of chaperones and intracellular retention of mutant protein (Gould 
et al. 2007) suggest that ER stress may also play a role in disease pathogenesis. Currently 
the contributions of ER stress and BM defects to phenotypes remains to be determined. 
Either way the mutations act in a dominant fashion as the absence of a phenotype in 
Col4a1/Col4a2+/- (Poschl et al. 2004) mice excludes haploinsufficiency as an underlying 
mechanism. Moreover, the phenotypes are influenced by genetic modifiers, as in mice the 
anterior segment dysgenesis (see below) is dependent on genetic background (Gould et al. 
2007). 
The observations of polycystic kidney disease in HANAC syndrome, and in a hypomorphic 
mouse model of Laminin alpha 5 (Lama5neo/neo) (Shannon et al. 2006), has placed emphasis 
on the role of the BM in cystic kidney disease. However, the mechanisms underlying cyst 
formation remain elusive and may be different in the two models. Whilst HANAC 
syndrome patients have altered tubular BMs, suggesting a structural defect (Plaisier et al. 
2007), Lama5neo/neo mice do not display overt BM abnormalities raising the hypthesis that 
laminin α5 plays a role in tubular epithelium homeostasis (Shannon et al. 2006). Further 
analysis of these models may reveal novel insights into the pathogenesis of cystic kidney 
disease. 
 
LAMB2 gene mutations, Pierson syndrome and the GBM as filtration barrier 
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Pierson syndrome is an autosomal recessive congenital disorder characterised by 
microcoria (extremely narrow non-responsive pupils), additional ocular abnormalities, and 
nephrotic syndrome leading to kidney failure before or immediately after birth (Gubler 
2008). It is caused by LAMB2 gene mutations, which result in absence or severe reduction 
of laminin β2 in tissues (Zenker et al. 2004). Different missense and nonsense mutations 
result in great clinical variability, possibly due to variations in expression levels, as not all 
patients with missense mutations have ocular defects (Choi et al. 2008; Hasselbacher et al. 
2006).  
Due to better management of renal problems, Pierson syndrome patients’ life expectancy 
has increased and led to the manifestation of a neuromuscular phenotype in some 
individuals (Maselli et al. 2009; Wuhl et al. 2007). These defects include invasion of 
Schwann cell in the synaptic space and structural defects leading to muscle weakness and 
fatigability (Maselli et al. 2009), symptoms also observed in Lamb2-/- mice (Patton et al. 
1998). The mice also exhibit congenital nephrosis (Noakes et al. 1995b), retinal defects 
(Libby et al. 1999) and failure to thrive. Elegant transgenic rescue experiments in Lamb2-/- 
mice showed that restoring renal and synaptic Lamb2 expression is required for a complete 
recovery and that the NMJ defects cause a failure to thrive (Miner et al. 2006). The 
congenital nephrosis is characterised by the effacement of podocyte foot processes 
reflecting the important structural role of laminin β2 in the GBM for anchoring the foot 
processes (Noakes et al. 1995b). Importantly, proteinuria and GBM permeability preceded 
podocyte defects in Lamb2-/- animals showing that the GBM is an active filtration barrier, 
in addition to the slit diaphragm present between foot processes (Jarad et al. 2006). 
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Proteoglycans and kidney function  
The presence of mild glomerular, tubular and filtration defects in Col18a1-/- mice 
(Utriainen et al. 2004) and renal abnormalities in Knobloch syndrome (see below) 
(Williams et al. 2008) indicate the importance of collagen type XVIII, a proteoglycan, in 
kidney function and urine filtration.  
The kidney filtration barrier provides both a size and charge selective barrier and the GBM 
and its charge were considered to be important in this context. The negative charge of the 
GBM is provided by side chains of the heparin sulphate proteoglycans (Kanwar et al. 1980) 
perlecan, collagen type XVIII and agrin. Charge barrier dysfunction may contribute to 
glomerular diseases (Myers et al. 1982) as a loss of heparan sulphate has been observed in 
diseases such as diabetic nephropathy (Tamsma et al. 1994). This hypothesis was supported 
by the presence of proteinuria in mice following enzymatic removal of heparan sulphate 
side chains (Comper and Glasgow 1995) and in HSPG2Δ3/Δ3 mice following administration 
of super physiological levels of BSA (Morita et al. 2005). However, the role of heparan 
sulphate side chains remains elusive as HSPG2Δ3/Δ3 mice have normal basal kidney function 
and no pathology under unchallenged conditions (Rossi et al. 2003). In addition, agrin 
deficiency, which affects the anionic charge of the BM, does not affect the filtration of a 
negatively charged tracer (Harvey et al. 2007) and HSPG2Δ3/Δ3 Agrndel/del mice, deficient for 
both perlecan heparin sulphate side chain and agrin, do not present with proteinuria 
(Goldberg et al. 2009). Therefore, the results cast doubt on the role of the GBM in charge 
selection and suggest a role for the endothelial glycocalyx (Harvey et al. 2007).  
 
Eye 
Knobloch Syndrome 
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Knobloch syndrome is an autosomal recessive disease characterised by high myopia (short 
sightedness), vitreoretinal degeneration, retinal detachment, macular abnormalities and 
occipital encephalocele. It can be caused by COL18A1 mutations resulting in truncation or 
loss of protein due to nonsense mediated decay (Sertie et al. 2000; Suzuki et al. 2002) but is 
genetically heterogeneous as additional loci have been identified (Khaliq et al. 2007; 
Menzel et al. 2004). This genetic heterogeneity combined with genetic modifiers (Utriainen 
et al. 2004) may underlie the highly variable clinical presentation of Knobloch syndrome. 
Due to the rarity of the syndrome and subsequent lack of human histopathology, most of 
what we know about Knobloch syndrome and its pathways has been based on analysis of 
Col18a1-/- mice.  
The persistence of the hyaloid vasculature, which is present in the vitreous body during 
development but regresses subsequently, is a feature of Knobloch syndrome (Duh et al. 
2004) and Col18a1-/- mice in which it is associated with defective growth of the retinal 
vasculature (Fukai et al. 2002). The hyaloid vasculature abnormalities may be due to 
changes in the inner limiting membrane leading to abnormal retinal attachment (Fukai et al. 
2002; Hurskainen et al. 2005) and/or due to a loss of frizzled domain function as observed 
due to a loss of function of frizzled 5 (Liu and Nathans 2008) and frizzled 4 (Marneros and 
Olsen 2005). Altered VEGF signalling (Fukai et al. 2002; Hurskainen et al. 2005) may then 
cause the retinal vasculature defects as VEGF mutant animals exhibit persistence of hyaloid 
vasculature (Stalmans et al. 2002) and VEGF can bind to heparan sulphate, suggesting a 
role for collagen type XVIII in VEGF signalling (Hurskainen et al. 2005). Normal retinal 
vascularisation is driven by hypoxia induced VEGF expression in astrocytes. The persistent 
hyaloid vasculature could then cause an absence of hypoxia (Fukai et al. 2002) and/or 
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alterations in endothelial cell or astrocyte function or behaviour (Hurskainen et al. 2005), 
thereby affecting VEGF signalling and retinal vasculature development. 
It is unlikely that these vascular defects underlie the progressive loss of vision in Knobloch 
syndrome patients and Col18a1-/- animals (Marneros and Olsen 2005) as they do not affect 
retinal perfusion or function (Marneros et al. 2004). A more likely explanation may be the 
accumulation of deposits between the retinal pigment epithelium and Bruch’s membrane, 
which are also observed in age related macular degeneration, possibly due to BM defects in 
Bruch’s membrane (Marneros et al. 2004).  
 
Eye diseases and collagen type IV mutations 
Given the wide expression pattern of α1.α1.α2(IV) it is not surprising that COL4A1 
mutations affect multiple tissues, including the eye. The ocular aspects of HANAC 
syndrome include retinal tortuosities (a tortuous appearance of the retinal vasculature) and 
haemorrhaging (Plaisier et al. 2007), which have also been observed in adult small vessel 
disease and porencephaly caused by COL4A1 mutations (Gould et al. 2005; Gould et al. 
2006), indicating that retinal tortuosities may be a common and characteristic phenotype of 
COL4A1 mutations. The retinal tortuosities is one of a number of vascular phenotypes 
affecting the eye that include a silvery appearance of the arterioles, retinal bleeding, and 
neovascularisation (Favor et al. 2007; Van Agtmael et al. 2005). Besides the vascular BM, 
COL4A1 and Col4a2 mutations also affect BMs of the anterior structures of the eye 
resulting in cataract formation and anterior segment dysgenesis including Axenfeld-Rieger 
anomaly (Favor et al. 2007; Gould et al. 2007; Sibon et al. 2007; Van Agtmael et al. 2005).  
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Although Alport’s syndrome is primarily a renal disease, patients can display ocular 
phenotypes including dot fleck retinopathy, lenticonus and cataract (Hudson et al. 2003). 
The formation of cataracts in patients with Alport’s syndrome or COL4A1 mutations 
indicates that the different collagen type IV networks present in the lens capsule are not 
redundant. However, the mechanisms underlying cataract formation remain elusive as both 
BM defects (Van Agtmael et al. 2005) and ER stress (Gould et al. 2007; Van Agtmael et al. 
2005) may contribute to the phenotype. Currently it is not clear how collagen type IV 
mutations result in the ocular phenotypes.  
 
Vascular disease and collagen type IV mutations 
The vascular BM surrounds the smooth muscle cells and separates them from endothelial 
cells. The importance of BM proteins in vascular disease was identified by the 
identification of COL4A1 mutations in porencephaly (cerebral spinal fluid filled cavities 
due to haemorrhagic stroke), recurrent cerebral and retinal microbleeds, 
leukoencephalopathy, retinal tortuosities and ischemic lacunar infarcts (Breedveld et al. 
2006; Favor et al. 2007; Gould et al. 2005; Plaisier et al. 2007; van der Knaap et al. 2006). 
Col4a1 mutations also weaken the vessel wall of the major vasculature as shown by 
intracranial aneurysms in the carotid artery (Plaisier et al. 2007; van der Knaap et al. 2006). 
These vascular defects may occur in isolation or be part of wider syndrome affecting the 
eye and kidneys (Plaisier et al. 2007; Sibon et al. 2007; Vahedi et al. 2007a).  
Thus far, no human COL4A2 mutations have been identified, but in mice Col4a2 mutations 
result in similar but less severe phenotypes than Col4a1 mutations. The milder phenotype 
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may be due to α1.α1.α2(IV) network composition, with the mutant alpha chain being 
present in 50% of protomers, as compared to 75% in case of a Col4a1 mutation. 
The variable clinical severity of patients with COL4A1 mutations depends on the type and 
position of the mutation, and genetic and environmental modifiers (Gould et al. 2007; 
Gould et al. 2006; Van Agtmael et al. 2005). The reduced penetrance of perinatal cerebral 
haemorrhaging (Gould et al. 2005), and increased survival in mouse pups born by 
Caesarean delivery (Gould et al. 2006) indicates birth trauma is an environmental risk 
factor, at least in some cases as embryonic porencephaly does occur (Favor et al. 2007). In 
addition, the occurrence of cerebral haemorrhages during sports activities (Vahedi et al. 
2007b) also suggests exercise as a risk factor. 
These data combined with the identification of a COL4A1 mutation in patients without a 
family history of haemorrhagic stroke (Vahedi et al. 2007b) and the association of 
extracellular matrix proteins with intracranial aneurysms (Ruigrok et al. 2006) raise the 
important question whether collagen type IV plays a role in stroke in general.  
 
Muscle and the neuromuscular junction (NMJ) 
Each muscle fibre is ensheathed by a BM, and at the NMJ a highly specialised BM is 
present in the synaptic cleft. The BM is not only important for NMJ development but also 
for the functions of the NMJ and the muscle. 
 
Merosin deficient congenital muscular dystrophy 
Merosin-deficient congenital muscular dystrophy 1A (MDC1A) is the most frequent form 
of congenital muscular dystrophy in which patients present with hypotonia, muscle 
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weakness and joint contractures at birth or within the first months of life and is caused by 
LAMA2 mutations (Helbling-Leclerc et al. 1995; Xu et al. 1994b). MDC1A patients also 
display central and peripheral neuropathy including white matter changes, and 
neuromigration and nerve conduction abnormalities probably due to myelination defects 
which have also been observed in the mouse models. The majority of LAMA2 mutations 
(Helbling-Leclerc et al. 1995; Xu et al. 1994b) result in the absence or severe reduction of 
LM-211 staining in the BM although recently a mouse model was described carrying a 
Lama2 missense mutation with normal Lama2 expression (Patton et al. 2008). In muscle 
the dystrophin-glycoprotein complex, links the cytoskeleton to the basement membrane 
through the binding of dystroglycan with the LG domains of laminin α2. Similar to 
mutations that affect the structure of the complex and the glycosylation of dystroglycan 
(which binds laminin α2) (Jimenez-Mallebrera et al. 2005), the LAMA2 mutations may 
result in muscular dystrophy by affecting the interaction between the dystrophin-
glycoprotein complex and the BM (Hall et al. 2007; Moll et al. 2001), by the failure to form 
a laminin network (Colognato and Yurchenco 1999) and by forming an abnormal BM due 
to defects in LN domain function (Patton et al. 2008). The description of mutations in 
integrin α7, which binds laminin, in muscular dystrophy patients (Jimenez-Mallebrera et al. 
2005) underlines the central role of the interactions between laminin and its cell surface 
receptors. Importantly improving the interaction between laminin and dystroglycan through 
the administration of linker molecules or agrin ameliorates the dystrophy in mice (Meinen 
et al. 2007; Moll et al. 2001), which was also observed through inhibition of apoptosis by 
increased BCL2 expression (Dominov et al. 2005; Girgenrath et al. 2004), thereby 
providing potential therapeutic avenues. 
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 Schwartz- Jampel Syndrome and dyssegmental dysplasia Silverman-Handmaker type  
Two allelic disorders, Schwartz-Jampel syndrome (SJS) and dyssegmental dysplasia 
silverman handmaker type (DDSH), are caused by HSPG2 mutations. SJS is a non lethal 
recessive disorder characterised by myotonia (muscle stiffness) with repetitive muscle 
discharges and chondrodysplasia (Nicole et al. 2000). DDSH is a neonatal lethal autosomal 
recessive syndrome characterised by short limbed dwarfism and encephalocele. The clinical 
outcome is determined by the amount of perlecan in the tissue as absence of perlecan 
secretion results in DDSH (Arikawa-Hirasawa et al. 2001), whilst a reduced secretion and 
partially functional perlecan underlies SJS (Nicole et al. 2000). 
Both DDSH and SJS patients, and Hspg2-/- and Hspg2C1532Y (carrying a C1532Y HSPG2 
mutation causing SJS) mice (Arikawa-Hirasawa et al. 1999; Rodgers et al. 2007; Stum et 
al. 2008) display chondrodysplasia which is characterised by severe disorganisation of 
chondrocytes and reduced extracellular matrix deposition. The requirement of perlecan for 
collagen fibrillogenesis in chondroplasts (Kvist et al. 2006) suggest that defective 
deposition of fibrillar collagen underlies the reduced matrix deposition. Moreover it 
indicates that perlecan anchors the BM to connective tissue (Bengtsson et al. 2002).  
In the NMJ acetylcholine excites the muscle and is degraded by acetylcholinesterase 
(AchE). Clustering of AchE in the NMJ is dependent on perlecan (Arikawa-Hirasawa et al. 
2002). The permanent myotonia in SJS patients is caused by reduced perlecan secretion 
leading to partial AChE deficiency. This may result in re-excitation of muscle leading to 
myotonia in SJS and muscle potentiation and a prolonged decay time of the potential in 
Hspg2C1532Y mice (Stum et al. 2008). In mice both myotonia and chondrodysplasia 
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phenotype severity is determined by the level of perlecan secretion and may also be 
influenced by age and genetic modifiers (Rodgers et al. 2007; Stum et al. 2008). However 
the spontaneous muscle activity at rest in SJS patients may not be caused by AChE 
deficiency as it did not result in spontaneous activity in diaphragm muscle in mice (Stum et 
al. 2008), but may be due to axonal defects (Echaniz-Laguna et al. 2009).  
Although NMJ disorganisation does not underlie the myotonia in SJS patients, the 
basement membrane plays a crucial role in NMJ organisation, maturation and function 
(Patton 2003; Sanes 2003). A complete review of this is outside the scope of this article but 
a few examples will be mentioned. For example laminin α4 is important for the alignment 
of pre and post synaptic nerve endings (Patton et al. 2001) whilst laminin α5 is required for 
postsynaptic maturation (Nishimune et al. 2008). Lamb2 mutations result in presynaptic 
defects (Noakes et al. 1995a) leading to failure to thrive in Lamb2-/- mice, a model for 
Pierson syndrome. In addition Col18a1 mutations result in neuromigration and axon 
guidance defects (Ackley et al. 2001) which may underlie the exencephaly in Knobloch 
syndrome and collagen type IV is important for clustering of synaptic vesicles and 
maintenance of mature synapses (Fox et al. 2007). 
 
Skin 
The dermal-epidermal junction (DEJ) in skin is an example of a highly complex form of 
BM and of specific divergence in its structure. This type of BM underlies stratifying 
squamous epithelia in the skin and mucous membranes of the orifices. It binds the basal 
cells of the epidermis with the dermis and provides structural adhesion and regulates 
epithelial-mesenchymal interactions (Aumailley et al. 2006). The DEJ contains 
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ultrastructurally recognizable suprastructures, such as the hemidesmosome complex in the 
basal cells, the anchoring filaments extending throughout the lamina lucida, and the 
anchoring fibrils emanating into the dermis. The molecular components of 
hemidesmosomes, anchoring filaments, and anchoring fibrils in the DEJ are quite well 
characterized, and mutations in their genes lead to diminished adhesion of the epidermis 
and the dermis, and to skin blistering. 
 
Epidermolysis bullosa 
The term epidermolysis bullosa (EB) covers genetic skin disorders characterised by muco-
cutaneous blistering and chronic epithelial fragility induced by minor shearing forces or 
trauma (Aumailley et al. 2006). The clinical symptoms vary from mild to severe and 
include continuous skin blistering, persistent erosions and mucosal involvement, nail 
dystrophy, alopecia, progressive soft tissue scarring, mutilating deformities and increased 
risk of epithelial cancer. Complications occur, since many organs are secondarily affected, 
e.g. the eye, the gastrointestinal, respiratory and urogenital tracts, scarring contractures of 
the joints, and even muscles to some extent.   
Depending on the affected molecular suprastructure, four main categories of EB are 
recognized: EB simplex, junctional EB, dystrophic EB and the Kindler syndrome (Fine et 
al. 2008). Whilst EB simplex and Kindler syndrome result from intracellular anomalies in 
keratinocytes, the junctional and dystrophic forms can be considered true BM diseases.  
  
Junctional epidermolysis bullosa 
Junctional EB is caused by mutations in the genes encoding laminin 332 (LAMA3, LAMB3, 
and LAMC2), and collagen XVII (COL17A1) (Kern and Has 2008). Dermal-epidermal 
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separation occurs at the level of the lamina lucida within the BM, and the hemidesmosome-
anchoring filament complex appears rudimentary. The most severe EB subtype, the Herlitz 
variant, results from absence of LM-332 from the skin due to null mutations in the laminin 
genes LAMA3, LAMB3, or LAMC2. The majority of mutations are found in LAMB3 (Varki 
et al. 2006) and the disease is characterized by congenital muco-cutaneous fragility leading 
to widespread blisters and erosions. At some stage, the healing of the skin ceases due to 
depletion of epidermal stem cells (Mavilio et al. 2006), and large chronically erosive areas 
lead to extensive fluid and protein loss, infection and lethal complications within the first 
year of life. 
In less severe junctional EB cases, the symptoms range from localized to generalized skin 
blistering, with onset at birth or later in life. These milder cases are due to missense 
mutations in LAMA3, LAMB3, LAMC2 or COL17A1 which result in truncated or misfolded 
LM-332 or collagen type XII proteins. These may become degraded intracellularly 
(Bateman et al. 2009) or, if secreted, interfere with ligand interactions between LM-332 and 
collagen XVII, or other extracellular matrix proteins (McGrath et al. 1995; Nakano et al. 
2002). Alternatively, misfolded molecules may be subjected to secondary degradation by 
tissue proteinases (Tasanen et al. 2000). 
Rare variants include junctional EB with pyloric atresia and the laryngo-onycho-cutaneous 
(LOC) syndrome. The former results from mutations of α6β4 integrin, a LM-332 ligand, 
and the latter from LAMA3 frame shift mutations, which abrogate the laminin α3A isoform. 
This isoform is secreted by the basal keratinocytes of stratified epithelia suggesting that 
LOC is caused by dysfunction of keratinocyte-mesenchymal communication (McLean et al. 
2003). 
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 Dystrophic epidermolysis bullosa 
Mutations in the gene for collagen type VII, COL7A1, cause recessive and dominant forms 
of dystrophic EB and the spectrum of biologic and clinical phenotypes is very broad (Kern 
and Has 2008). Tissue separation occurs at the level of the anchoring fibrils in the 
uppermost dermis, and the fibrils, if present, exhibit an altered ultrastructure. In all forms of 
dystrophic EB the blisters heal with scarring, i.e. dermal fibrosis. Patients with dominant 
dystrophic EB have a rather mild phenotype, mostly limited to hand and feet which is 
usually caused by dominant negative interference by glycine substitutions within the triple 
helical domain. Recessive dystrophic EB is caused by homozygosity or compound 
heterozygosity for two different COL7A1 mutations which can be nonsense, missense or 
splice site mutations. In the majority of severe generalized recessive dystrophic EB cases, 
both mutations generate premature termination codons leading to nonsense mediated decay 
and complete absence of collagen type VII. In this severe EB subtype progressive blistering 
leads to chronic wounds, extensive scarring and mitten deformities of hands and feet. Oral 
and gastrointestinal involvement leads to malnutrition, which in combination with protein 
loss through ulcerations, results in growth retardation and anaemia.  
 
Mouse models for epidermolysis bullosa   
Ablation or disruption of genes coding for the α3, β3 or γ2 chains of LM-332, or for the 
integrin α6 or β4 subunits in mice lead to junctional EB with absence of hemidesmosomes, 
severe detachment of the epidermis from the dermis and in perinatal death (Aumailley et al. 
2006). Deficiency of collagen type XVII leads to a milder phenotype of junctional EB 
 31
displaying moderate skin blistering, nail dystrophy, alopecia and dental anomalies (Nishie 
et al. 2007), similar to the human pathologies caused by COL17A1 mutations. The clinical 
and morphologic characteristics of recessive dystrophic EB in humans were recapitulated in 
two different mouse models with complete (Heinonen et al. 1999) or partial deficiency of 
collagen type VII (Fritsch et al. 2008). The mice with abrogation of LM-332, α6β4 integrin 
or collagen type VII expression, with phenotypes of severe blistering and perinatal lethality, 
have been helpful for understanding the functional role of these proteins in skin 
morphogenesis and homeostasis. Particularly interesting are mice with milder phenotypes, 
e.g. the collagen type VII hypomorph or the collagen type XVII knockout mouse, which are 
useful for testing novel biologically valid therapeutic strategies, including protein, cell and 
gene based therapies, which have already shown some promising  results (Fritsch et al. 
2008; Kern et al. 2009; Mavilio et al. 2006).  
 
Acquired autoimmune diseases targeting basement membranes 
Goodpasture’s syndrome 
Goodpasture syndrome is an autoimmune disease with anti-GBM antibodies that results in 
glomerulonephritis and frequently lung haemorrhaging. The renal injury is the consequence 
of complement and protease activation which disrupts the filtration barrier leading to 
proteinuria, and an immune response ultimately causing fibrosis (Hudson et al. 2003). The 
antibodies react with two major epitopes in the NC1 domain of the α3(IV) chain. These are 
located near the junction of the NC1 and triple helical domains, where they are masked by 
the hexamer structure (Borza et al. 2002). Consequently, antibodies only gain access to the 
epitopes following hexamer dissociation (Borza et al. 2002). Unmasking of the epitopes 
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may be influenced by additional external factors such as reactive oxygen species (Kalluri et 
al. 2000) but in vitro evidence also shows that hexamer structure and stability determines at 
least in part the ability of the antibodies to unmask the epitopes (Borza et al. 2005). 
Moreover, MHC class is a modifier of the disease (Hudson et al. 2003) as the severity of 
Goodpasture syndrome is determined by MLA class.  
The production of antibodies against the GBM can also occur in Alport's syndrome 
patients. Following kidney transplantation, the presence of “foreign” collagen IV chains 
can cause Alport's posttransplantation anti-GBM nephritis. In autosomal recessive Alport's 
syndrome the epitopes are located in the NC1 domains of Col4a3 or Col4a4 (Hudson et al. 
2003; Wang et al. 2005) whilst X-linked patients develop alloantibodies targeting epitopes 
on COL4A5 (Brainwood et al. 1998; Kang et al. 2007). However in contrast to the cryptic 
Goodpasture epitopes, the epitopes are accessible in the NC1 hexamer indicating that 
separate mechanisms may exist (Kang et al. 2007).  
 
Bullous pemphigoid 
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, which 
typically affects the elderly and is associated with circulating and tissue-bound 
autoantibodies to collagen XVII. Clinically, tense serous blisters on inflamed skin give rise 
to erosions and wounds. During the course of the disease, localized blister formation 
progresses into generalized erosive dermatitis. The pathogenicity of autoantibodies against 
collagen type XVII in BP is supported by extensive clinical and experimental evidence 
(Sitaru 2009). The major pathogenic epitopes are located in the juxtamembranous NC16A 
domain of collagen type XVII (Fig 2D). The NC16 domain is also the site of cleavage for 
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the ectodomain shedding (Franzke et al. 2009; Franzke et al. 2002) and this shedding and 
epitope recognition by pemphigoid autoantibodies is regulated by the phosphorylation 
status of collagen type XVII (Zimina et al. 2008).  
 
Epidermolysis bullosa acquisita 
Epidermolysis bullosa acquisita is a rare acquired autoimmune subepidermal blistering 
disease of the skin, which derives its name from the similar phenotype to dystrophic EB 
(Mihai and Sitaru 2007; Woodley et al. 2007). It is characterized by IgG autoantibodies 
against epitopes located in the NC1 domain of collagen type VII, the major component of 
anchoring fibrils. Murine models have demonstrated the pathogenicity of the autoantibodies 
(Sitaru et al. 2005), which are likely to perturb the functions of ligand binding sites within 
the NC1 domain, e.g. for LM-332.  
 
Therapeutic perspectives  
The rapid increase of knowledge about causes and mechanisms of certain BM diseases has 
allowed the scientific community to embark on development of molecular therapy 
strategies. Indeed, many genetic BM disorders are very severe, and the development of 
molecular therapy approaches is urgently needed. Although the clinical application of such 
therapies is still in the future, new technologies hold promise for individually designed and 
biologically valid, evidence-based treatments. Based on present knowledge, treatments with 
protein-, cell- and gene-based therapies seem possible. However, it is also clear that a large 
gap still exists between laboratory experiments and the successful treatment of a patient. 
For most diseases there is an urgent need to acquire the higher level of understanding of the 
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molecular and cellular consequences of the mutations. However, despite this some marked 
progress has been made. 
Skin disorders have been the prime focus of therapy developments, since the target organ is 
easily accessible for both therapeutic measures and for analysis of their macroscopic, 
microscopic and molecular effects. Recent studies in animal models revealed that relatively 
small biological changes, e.g. moderately increased levels of a missing protein in the skin, 
can have substantial clinical effects. Therefore, a large number of patients with genetic skin 
disorders will at this point not expect a complete cure, but welcome any biologically valid 
advances that reduce symptoms, improve functionality or increase quality of life 
A relatively broad spectrum of approaches– ranging from protein therapy (Ortiz-Urda et al. 
2003; Remington et al. 2009) and viral-mediated gene transfer (Baldeschi et al. 2003; 
Ortiz-Urda et al. 2002; Seitz et al. 1999) to cell therapy (Fritsch et al. 2008; Kern et al. 
2009; Wong et al. 2008) and bone marrow transplantation (Tolar et al. 2009) – has been 
employed in mouse models and single patients. The correction of junctional EB by 
transplantation of genetically modified epidermal stem cells in one patient represents the 
first long-term clinical therapeutic success in genetic BM disease (Mavilio et al. 2006). A 
cell-therapy approach with intradermal injections of allogeneic wild type or gene-corrected 
fibroblasts in mice and humans with recessive dystrophic EB showed that these cells can 
increase collagen VII content at the DEJ (Fritsch et al. 2008; Kern et al. 2009; Wong et al. 
2008; Woodley et al. 2003). A long-term study with fibroblast treatment of the collagen VII 
hypomorphic mouse, a model for recessive dystrophic EB, demonstrated that high stability 
of collagen VII contributes to positive long-term effects. The injected fibroblasts 
synthesized collagen VII for 3-4 weeks and increased its levels to about 35 % of normal. 
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The newly synthesized collagen persisted in the skin up to 4 months, stabilized it 
substantially against shearing forces and ameliorated the phenotype significantly (Kern et 
al. 2009) without notable adverse effects. As similar observations were made in a pilot 
study in human skin (Wong et al. 2008), intradermal injections of normal fibroblasts may 
represent a first causal therapy for dystrophic EB that could be expected to increase the 
resistance of the skin against external shearing forces and alleviate skin blistering and 
scarring in trauma-exposed skin areas. 
Yet another approach has been direct intradermal injection of recombinant human collagen 
type VII into the Col7a1-/- mouse (Remington et al. 2009). The injected collagen was 
present as the DEJ but it also diffused into distant sites and persisted in the skin for about 2 
months. This improved the phenotype, as shown by decreased skin blistering and prolonged 
survival of the animals. The findings are intriguing as they suggest that injections of 
monomeric collagen type VII, a component of highly specific supramolecular polymers, 
can result in phenotypic improvement. However, it remains unclear, how collagen type VII 
homes to the DEJ and how long it and its specific aggregates, the anchoring fibrils, would 
remain stable and functional in the skin (Bruckner-Tuderman 2009). 
Very recent reports have implicated bone marrow/stem cell transplantation as a promising 
therapeutic approach in mouse models with different forms of EB or in Alport’s syndrome. 
The Col7a1-/- mouse, which is lethal within days after birth if untreated (Heinonen et al. 
1999), was transplanted with SLAM family receptor-positive (CD150+/CD48-) adult bone 
marrow or mesenchymal stem cells. This led to the survival of some mice, to skin 
engraftment of donor cells and to improved skin stability (Tolar et al. 2009). However, 
collagen type VII was not detected at the DEJ. Embryonic bone marrow transplantation in 
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Col7a1-/- mice resulted in detection of bone marrow-derived fibroblasts in the dermis, 
ameliorated the clinical phenotype of the mice and led to collagen type VII deposition 
primarily in the follicular BM (Chino et al. 2008).  
Similarly, wild-type bone marrow-derived cells can ameliorate the phenotype in Alport 
mice by secreting the missing collagen a3.α4.α5(IV) network (Gross et al. 2009). It was 
postulated that circulating bone marrow-derived cells are recruited to glomeruli where they 
can cross the GBM, become podocytes, secrete the missing collagen chains, repair the 
GBM defects, and slow (if not reverse) disease. Intriguingly, Katayama et al (Katayama et 
al. 2008) reported that bone marrow transplantation following lethal irradiation with either 
wild-type or Col4a3-/- bone marrow prolonged the lifespan of Alport mice with similar 
efficiencies. Sublethal irradiation alone also provided significant benefits (Gross et al. 
2009).  
Taken together, exciting advancements in designing effective therapies, such as described 
above, provide new avenues for research on these incurable diseases that ultimately will 
facilitate translation to clinics and establishing therapy protocols for the management of 
genetic BM diseases. 
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Table 1: Human diseases and basement membrane proteins 
 
Table 2; Phenotypes of mouse models of BM components covered in text 
 
Figure 1. Schematic diagram of the general cruciform shape of laminin proteins. Rod 
shaped and Y shaped laminin occur due to incorporation of truncated α3 and α4, and γ2 
chains respectively. The N-terminal end of the chains contains globular domains separated 
by laminin epidermal growth factor-like repeats (LEa, LEb, LEc). All chains contain 
laminin N-terminal (LN) domains which are important for laminin network formation. The 
α chain also contain the L4a and L4b globular domains whilst β and γ chains contain the 
LF and L4 domains respectively. The C-terminal end of the α chain forms the globular LG 
domain consisting of five LG (numbered 1-5).  
 
Figure 2. Schematic diagram of BM collagens (A) Collagen type IV protomer structure 
consists of a central collagen domain flanked by the N-terminal 7S domain and C-terminal 
NC1 domain. Interactions with integrin receptors occur through sequences in the GB3 
domain and NC1 domain. (B) The central collagen domain of Collagen type XVIII contains 
interruption in Gly-X-Y repeat and is flanked by the N-terminal non collagenous domain 
and a C-terminal NC1 domain harbouring the endostatin fragment. The N-terminal domain 
contains the heparan sulphate side chains. (C) The intracellular domain of collagen type 
XVII contains four tandemly arranged 24-amino-acid repeats and four membrane-proximal 
cysteine residues. The ectodomain contains interrupted collagenous domains, the NC16a 
domain which harbours the ADAMS cleavage site, and a flexible tail. (D) Collagen type 
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VII has a central collagen domain flanked by the N-terminal NC1 domain and the NC2 
domain which is proteolytically cleaved. 
 
Figure 3 Schematic diagram of perlecan structure. Perlecan Domain I is the attachment site 
for the heparan sulphate chains and contains a SEA (Sperm protein, Enterokinase, Agrin) 
module and three, closely-spaced SGD (Ser-Gly-Asp) tripeptide sequences. Domain II is 
homologous to the low density lipid (LDL) receptor ligand binding domain whilst domain 
III has three laminin-like domain modules and 8 epidermal growth factor (EGF)-like 
repeats. Domain IV contains N-CAM-like Ig repeats and binds other BM components. 
Domain V consists of laminin-like globular domains separated by four EGF like repeats. 
 
Figure 4. Nidogen consists of globular domains, important for interaction with other BM 
molecules, separated by rod like domains. 
 
Figure 5: (A) Col4a1 mutations lead to defects in Bowman’s Capsule consisting of 
hypertrophy of parietal epithelium. B) Anterior segment dysgenesis due to Col4a1 mutation 
includes corneal opacity (arrow) and Neovascularisation (arrowhead). (C) Buphthalmos and 
iris hypoplasia (arrow) can be observed in some animals. 
 
Figure 6 Dystrophic EB: consequences of mutations of the epidermal BM in the skin.  (A) 
A trauma-induced skin blister. (B) Scarring, inflammation and loss of nails are 
consequences of repeated blistering. (C) Immunofluorescence staining of normal human 
skin with antibodies to collagen type VII. Note the linear signal along the epidermal BM. 
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(D) In the skin of an individual with severe dystrophic EB, collagen type VII is missing as a 
consequence of nonsense mutations in the COL7A1 gene.  
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Table 1:  
Basement membrane protein targets in inherited human diseases 
Organ BMZ* component Affected 
gene(s) 
Disease 
Eye Collagen type IV 
 
 
 
Collagen type XVIII 
 
COL4A3 
COL4A4 
COL4A5 
 
Alport syndrome 
Cataract 
Axelfeld Rieger disease 
 
Knobloch syndrome 
Kidney Collagen type IV  
 
 
 
 
 
Laminin β2 
 
COL4A1 
 
COL4A3 
COL4A4 
COL4A5 
 
LAMB2 
 
HANAC syndrome 
 
Alport’s syndrome 
TBMN*/ 
 
 
Pierson syndrome 
 
Vasculature Collagen type IV 
 
 
 
 
COL4A1 
 
 
 
 
Hemorrhagic stroke 
Porencephaly 
HANAC syndrome 
 
 
Muscle Laminin α2 
 
 
Perlecan 
 
 
 
 
 
LAMA2 
 
 
HSPG2 
 
 
 
 
 
Merosin congenital 
muscular dystrophy 
 
Schwartz-Jampel 
syndrome 
Dystrophic dysplasia 
Silverman Handmaker 
 
 
Skin Collagen type XVII  COL17A1 
 
Junctional EB 
 Laminin 332 LAMA3 
LAMB3 
LAMC2 
 
LAMA3 
 
Junctional EB 
 
 
 
LOC** syndrome 
 Collagen type VII 
 
COL7A1 
 
Dystrophic EB 
 
* TBMN: thin basement membrane nephropathy 
** LOC: laryngo-oculo-cutaneous syndrome 
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Table 2 
Phenotypes of mouse models of BM components covered in text 
 
BMZ component Affected Gene Phenotype Reference 
Laminin Lama2 Merosin congenital 
muscular dystrophy 
 
(Patton et al. 2008; 
Xu et al. 1994a; Xu 
et al. 1994b) 
 Lama5 Tooth and lung 
development, 
glomerulogenesis  
polycystic kidney 
disease 
(Miner and Li 2000; 
Shannon et al. 2006) 
 Lamb1 Early embryonic lethal, 
lack of BM formation 
(Miner et al. 2004) 
 Lamb2 NMJ defect, congenital 
nephrosis, failure to 
thrive, retinal defects 
(Libby et al. 1999; 
Miner et al. 2006; 
Noakes et al. 1995a; 
Noakes et al. 1995b; 
Patton et al. 1998) 
 Lamc1 Early embryonic lethal, 
lack of BM formation, 
Renal agenesis, delayed 
lung development 
(Smyth et al. 1999; 
Willem et al. 2002) 
Collagen type IV Col4a1 Anterior segment 
dysgenesis, 
glomerulopathy, 
porencephaly, 
haemorrhagic stroke 
(Gould et al. 2007; 
Gould et al. 2005; 
Gould et al. 2006; 
Poschl et al. 2004; 
Van Agtmael et al. 
2005) 
 Col4a2 Anterior segment 
dysgenesis, 
haemorrhaging, 
porencephaly 
(Favor et al. 2007) 
 Col4a3 Proteinuria, kidney 
failure, Alport 
syndrome, thin basement 
nephropathy 
(Abrahamson et al. 
2007; Beirowski et 
al. 2006; Kang et al. 
2006) 
 Col4a5 X-linked Alport’s 
syndrome 
(Rheault et al. 2004) 
Collagen type VII Col7a1 recessive dystrophic EB (Fritsch et al. 2008; 
Heinonen et al. 
1999) 
Collagen type XV Col15a1 Cardiac and muscle 
phenotype 
(Eklund et al. 2001) 
Collagen type XVII Col17a1 non-Herlitz EB, growth 
retardation 
(Nishie et al. 2007) 
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Collagen type XVIII Col18 Knobloch syndrome, 
hydrocephalus, , renal 
filtration defect 
(Fukai et al. 2002; 
Hurskainen et al. 
2005; Marneros et 
al. 2004; Utriainen 
et al. 2004) 
Perlecan HSPG2 Developmental cardiac 
and cephalic defects, 
skeletal dysplasia, 
exencephaly, vascular 
defect, SJS, DDSH 
(Costell et al. 1999; 
Rodgers et al. 2007; 
Stum et al. 2008; 
Tran et al. 2004) 
Nidogen Nid1 No phenotype (Murshed et al. 
2000) 
 Nid 1 Nid2 NMJ maturation, 
syndactyly, cardiac 
phenotypes, delayed 
lung development, Bm 
defects in vasculature  
(Bader et al. 2005; 
Bose et al. 2006; 
Mokkapati et al. 
2008) 
 
 
 
 
 
 
 
 
